The NC-stat DPN Check is a diabetic peripheral neuropathy early detection system. The device measures sural nerve conduction velocity and response amplitude, the standard biomarkers for DPN. It also features an ergonomic and compact design, while being cost effective.
Waltham, Mass.-based NeuroMetrix and Omron previously made a deal for the distribution rights for the NC-stat in Japan, according to a press release.
“Omron has a strong and growing presence in China to compliment its global reach. We are building an effective working relationship with Omron as we navigate the Japan regulatory process and prepare for commercial launch. We are pleased to join with Omron in bringing NC-stat DPNCheck to the large Chinese diabetes market,” NeuroMetrix president & CEO Dr. Shai Gozani said in prepared remarks.
The news sent NURO share up 3.3% to a $3.10 close Dec. 10, the day the deal was announced. The stock was trading at $3.01 a piece today, down 3.8%, as of about 1:30 p.m.